Loading...
Loading...
Below are the diagnostic substances stocks on the NASDAQ in terms of revenue.
The trailing-twelve-month revenue at IDEXX Laboratories
IDXX is $1.34 billion. IDEXX's PEG ratio is 2.10.
The trailing-twelve-month revenue at Neogen
NEOG is $216.35 million. Neogen's ROE for the same period is 11.22%.
The trailing-twelve-month revenue at Abaxis
ABAX is $188.77 million. Abaxis's operating margin for the same period is 14.31%.
The trailing-twelve-month revenue at Meridian Bioscience
VIVO is $188.69 million. Meridian Bioscience had $40.36 million in total cash for the latest quarter.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in